Breaking: Moderna (MRNA) reassures its vaccine effectivity against new Covid-19 variants
- MRNA provides updates on studies with new Covid-19 variants.
- Moderna vaccine sees no significant change in its effectiveness against the UK variant.
- Protection against the South African variant is effective but at a lower level.
Moderna (MRNA) provided some reassuring news on Monday as it appears that its vaccine is effective against the UK and South African strains of the Covid-19 virus. “Vaccination with the Moderna Covid-19 vaccine produced neutralizing titers against all key emerging variants tested, including B1.1.7 and B.1.351 first identified in the UK and Republic of South Africa, respectively,” the company said.
However, the news should be greeted with some caution as the South African variant does appear to be harder to protect against. Moderna (MRNA) says “a six-fold reduction in neutralizing titers was observed with the B.1.351 variant relative to prior variants”.
Moderna still expects its vaccine to be above standard-efficacy levels needed to protect against the South African variant. “Despite this reduction, neutralizing titer levels with B.1.351 remain above levels that are expected to be protective”.
Moderna (MRNA) shares are trading 9% higher on Monday in early trading.
The author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
This article is for information purposes only. The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice. It is important to perform your own research before making any investment and take independent advice from a registered investment advisor.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to accuracy, completeness, or the suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. The author will not be held responsible for information that is found at the end of links posted on this page.
Premium
You have reached your limit of 3 free articles for this month.
Start your subscription and get access to all our original articles.
Author
Ivan Brian
FXStreet
Ivan Brian started his career with AIB Bank in corporate finance and then worked for seven years at Baxter. He started as a macro analyst before becoming Head of Research and then CFO.
